RE: ValiRx5 Sep 2023 10:45
Physiomics will receive a fee (capped at £6m) of 6% of any future net revenues that may be received by ValiRx relating to its commercialisation of VAL201 and its derivatives in any indication, including prostate cancer, endometriosis and treatment for Coronavirus infection. Eligibility for part of this fee will be conditional on completion of an agreed programme of work by Physiomics that builds on the work already carried out under the 2011 agreement. This programme of work will start on 15 February 2021 and is required to be completed by 15 November 2021. In recognition of the collaborative nature of this new agreement, Physiomics will also be offered a seat on the ValiRx scientific advisory board.